CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a clinical-stage neurotechnology company pioneering neuromodulation-based treatments for neurodegenerative diseases, announced five new poster ...
Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics. His stories explore how tech is changing the ...
- Data will highlight durability of treatment effect and significant impact on slowing disease progression. - No treatment-related serious adverse events (SAEs) or incidents of amyloid-related imaging ...
New findings highlight correlations between EEG and clinical outcome measures in Alzheimer’s disease Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results